biotech fireworks Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech fireworks

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tom pope	10/12/2005 9:25:07 AM
	Read Replies (1) of 7424

ICOS has been playing with the 15% level on this: Lilly ICOS midstage study of prostate drug meets goal Wed Oct 12, 2005 08:18 AM ET CHICAGO, Oct 12 (Reuters) - Lilly ICOS LLC, a joint venture between Eli Lilly and Co.(LLY.N: Quote, Profile, Research) and ICOS Corp.(ICOS.O: Quote, Profile, Research) said a trial studying its tadalafil treatment for enlarged prostate in a once-a-day dose met its primary goal and will advance to late-stage trials. Lilly ICOS said the once-daily drug was for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Currently, the drug is used on an as-needed basis. Tadalafil is the active ingredient in Cialis, a prescription drug approved for the treatment of erectile dysfunction

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next